Abstract
The brain remains an area where little corrective surgery can be performed and the reversal of damage is almost impossible. Recently, reports of agents offering neuroprotection have begun to appear in the literature. The concept of neuroprotection is the administration of some agent, which should reverse some of the damage or prevent further damage. Some agents offer protection against cell degeneration to the neuronal cells. Still other agents specifically protect the dopamine neurons and the retina. The majority of neuroprotective agents are antioxidants. An immunosuppressive calcineurin inhibitor, NOS inhibitor, σ-1 modulator, AMPA antagonist and Ca2+ channel blocker have all shown neuroprotective activity. An estrogen agonist and two glycoprotein IIb / IIIa antagonists also exhibit neuroprotective activity.Most of the synthetic compounds presented were not originally designed as neuroprotective agents but were found to possess neuroprotective activity in later studies. Many of these compounds are biologically active natural products, either plant extracts or endogenous peptides / proteins. This review will present the most recent reports on these agents.
Keywords: antioxidant, neuroprotection, calcineurin, neuroprotective, dopamine, retina, neurodegeneration, stroke
Current Medicinal Chemistry
Title: A Review of Neuroprotective Agents
Volume: 11 Issue: 18
Author(s): M. S. Levi and M. A. Brimble
Affiliation:
Keywords: antioxidant, neuroprotection, calcineurin, neuroprotective, dopamine, retina, neurodegeneration, stroke
Abstract: The brain remains an area where little corrective surgery can be performed and the reversal of damage is almost impossible. Recently, reports of agents offering neuroprotection have begun to appear in the literature. The concept of neuroprotection is the administration of some agent, which should reverse some of the damage or prevent further damage. Some agents offer protection against cell degeneration to the neuronal cells. Still other agents specifically protect the dopamine neurons and the retina. The majority of neuroprotective agents are antioxidants. An immunosuppressive calcineurin inhibitor, NOS inhibitor, σ-1 modulator, AMPA antagonist and Ca2+ channel blocker have all shown neuroprotective activity. An estrogen agonist and two glycoprotein IIb / IIIa antagonists also exhibit neuroprotective activity.Most of the synthetic compounds presented were not originally designed as neuroprotective agents but were found to possess neuroprotective activity in later studies. Many of these compounds are biologically active natural products, either plant extracts or endogenous peptides / proteins. This review will present the most recent reports on these agents.
Export Options
About this article
Cite this article as:
Levi S. M. and Brimble A. M., A Review of Neuroprotective Agents, Current Medicinal Chemistry 2004; 11 (18) . https://dx.doi.org/10.2174/0929867043364522
DOI https://dx.doi.org/10.2174/0929867043364522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cells in Abdominal Aortic Aneurysms
Current Vascular Pharmacology Heparin-Coated Extracorporeal Circulation Systems in Heart Surgery
Recent Patents on Cardiovascular Drug Discovery Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Radiological Screening Programs for Women at High Risk of Developing Breast Cancer
Current Women`s Health Reviews Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Assessment of Vascular Geometry for Bilateral Carotid Artery Ligation to Induce Early Basilar Terminus Aneurysmal Remodeling in Rats
Current Neurovascular Research MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry 3D CT Angiography of Infrarenal Abdominal Aortic Aneurysm with Associated Ectopic Pelvic Kidney: A Case Report of Rare Concomitance
Current Medical Imaging Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Prophylactic Neuroprotection
Current Drug Targets Which way in? The Necessity of Multiple Approaches to Transcatheter Valve Therapy
Current Cardiology Reviews Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets